From insulin and insulinlike activity to the insulin superfamily of growth-promoting peptides: A 20th-century odyssey

Perspectives in Biology and Medicine

Volumn 53, Issue 4, 2010, Pages 491-508

  Blumenthal, Stanley ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEXAPODA; MOLLUSCA; RATTUS; VERTEBRATA;

GROWTH HORMONE; INSULIN; NONSUPPRESSIBLE INSULIN LIKE ACTIVITY; SOMATOMEDIN;

ANIMAL; BLOOD; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; GROWTH HORMONE; HUMANS; INSULIN; NONSUPPRESSIBLE INSULIN-LIKE ACTIVITY; SOMATOMEDINS;

EID: 78149267283     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Akiyama, M., et al. 2002. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62:3876-3882
2. Antoniades,H.N. 1963. Properties of "free" insulin and insulin complexes in blood.Diabetes 12:365.
3. Armin, J., et al. 1961.Acute insulin deficiency provoked in the dog, pig and sheep by single injections of anti-insulin serum. J Physiol 157:64-73.
4. Backeljauw, P. F., and L.W. Underwood. 2001.Therapy for 6.5-7.5 years with recombi-nant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study. J Clin Endocrinol Metab 86:1504-1510
5. Baker, J., et al. 1993. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73-82.
6. Batchelor, B. R.1967. Insulin-like activity. Diabetes 16:418-434
7. Berson, S.A., and R. S.Yalow. 1965. Some current controversies in diabetes research.Diabetes 14:549-572
8. Bondy, C.A. et al. 1994. Clinical uses of insulin-like growth factor I. Ann Int Med 120: 593-601.
9. Butler,A.A., and D. LeRoith. 2001.Control of growth by the somatotropic axis:Growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 63:141-164
10. Camirand, A. et al. 2005. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7:R570-R579.
11. Chan, S. J., Q. Cao, and D. Steiner. 1990. Evolution of the insulin superfamily: Cloning of a hybrid insulin/insulin-like growth factor cDNA from amphioxus. Proc Natl Acad Sci USA 87:9319-9323
12. Chan, S. J., and D. Steiner. 2000. Insulin through the ages: Phylogeny of a growth promoting and metabolic regulatory hormone. Am Zool 40:213-222
13. Cohen, B.D., et al. 2005.Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073
14. Cosaceanu, D., et al. 2007. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.Growth Factors 25:1-8.
15. Daughaday,W.H., et al. 1972. Somatomedin: Proposed designation for sulphation factor. Nature 235:107.
16. Daughaday,W. H., et al. 1987. On the nomenclature of the somatomedins and insulinlike growth factors. J Clin Endocrinol Metab 65:1075-1076
17. DeChiara,T. M.,A. Efstratiadis, and E. J. Robertson. 1990.A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345:78-80.
18. DeChiara, T. M., E. J. Robertson, and A. Efstratiadis. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64:849-859
19. Delafontaine, P.,Y. Song, and L.Yangxin. 2004. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24:435-444
20. De Mellow, J. S. M., and R. C. Baxter. 1988. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Comm 156:199-204.
21. 3 and repressed by growth factors. J Biol Chem 284:10334-10342
22. Friedrich, N., et al. 2009. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 94:1732-1739
23. Froesch, E. R., et al. 1963.Antibody-suppressible and nonsuppressible insulin-like activ-ities in human serum and their physiologic significance:An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 42:1816-1834
24. Froesch, E. R., et al. 1974. NSILA-S: Insulin-like properties, receptor binding activities and relationship to somatomedin. Acta Endocr 184(suppl.):183-184
25. Gellhorn, E., J. Feldman, and A. Allen. 1941. Assay of insulin on hypophysectomized, adreno-demedullated, and hypophysectomized-adreno- demedullated rats. Endocrinol 29:137-140
26. Goberdhan, D. C. I., and C.A. R. Boyd. 2009. mTOR: Dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 37:213-216
27. Hall, K., and K.Uthne. 1971. Some biological properties of purified sulfation factor (SF) from human plasma. Acta Med Scand 190:137-143
28. Jirtle, R. L., and J. R.Weidman. 2007. Imprinted and more equal. Am Sci 95:143-149
29. Jones, J. I., and D.R.Clemmons. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
30. Klapper, D. G., M. E. Svoboda, and J. J.VanWyk. 1983. Sequence analysis of somatomedin- C: Confirmation of identity with insulin-like growth factor I. Endocrinol 112: 2215-2217
31. Kondo,T., et al. 2003. Knockout of insulin and IGF-I receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 111:1835-1842
32. Kupfer, S. R., et al. 1993. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 91:391-396
33. Leonards, J.R.,B.R. Landau, and G.Bartsch. 1962.Assay of insulin and insulin-like activity with rat epididymal fat pad. J Lab Clin Med 60:552-570
34. Liu, J., et al. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.
35. Martin, D. B.,A. E. Renold, and Y. M. Dagenais. 1958.An assay for insulin-like activity using rat adipose tissue. Lancet 2:76-77.
36. Megyesi, K., et al. 1975.The NSILA-s receptor in liver plasma membranes: Characterization and comparison with the insulin receptor. J Biol Chem 250:8990-8996
37. Morell, B., and E.R. Froesch. 1973. Fibroblasts as an experimental tool in metabolic and hormonal studies. II. Effects of insulin and nonsuppressible insulin-like activity (NSILA-S) on fibroblasts in culture. Eur J Clin Invest 3:119-123
38. Moses, A. C., et al. 1996. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100.
39. Muhlbradt, E., et al. 2009. NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Res 69:2615-2622
40. Nahor, I., et al. 2005.The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Hormone IGF Res 15: 388-396
41. Nichols, T. C., et al. 1999. Reduction in atherosclerotic lesion size in pigs by aVB3 inhibitors is associated with inhibition of insulin-like growth factor-1-mediated signaling. Circ Res 85:1040-1045
42. Oelz,O., et al. 1972.Antibody suppressible and nonsuppressible insulin-like activities. InHandbook of Physiology, ed.R.O.Greep and E. B.Astwood, 685-702.Washington,DC: American Physiological Society.
43. Papaconstantinou, J. 2009. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. Mol Cell Endocrinol 299:89-100.
44. Radulescu, R.T., et al. 2000. Nuclear colocalization and complex formation of insulin with retinoblastoma protein in HEPG2 human hepatoma cells. J Endocrinol 166:R1-R4.
45. Randle, P. J. 1954a. Assay of plasma insulin activity by the rat-diaphragm method. BMJ 1:1237-1240
46. Randle, P. J. 1954b. Plasma-insulin activity in acromegaly. Lancet 1:441-444
47. Randle, P. J. 1954c. Plasma-insulin activity in hypopituitarism. Lancet 1:809-810
48. Rinderknecht, E., and R.E. Humbel. 1976.Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: Evidence for structural homology with insulin B chain. Proc Natl Acad Sci USA 73:4379-4381
49. Rinderknecht, E., and R. E.Humbel. 1978a.The amino acid sequence of human insulinlike growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769-2776
50. Rinderknecht, E., and R. E. Humbel. 1978b. Primary structure of human insulin-like growth factor II. FEBS Lett 89:283-286
51. Roddam, A.W., et al. 2008. Insulin-like growth factors, their binding proteins, and prostate cancer risk:analysis of individual patient data from 12 prospective studies.Ann Intern Med 149:461-471
52. Salmon,W.D., andW.H.Daughaday. 1957.A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49:825-836
53. Samani, A. A., et al. 2007.The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28:20-47.
54. Samann, N., R. Fraser, andW. J. Dempster. 1963.The "typical" and "atypical" forms of serum insulin. Diabetes 12:339-348
55. Schoeffling, K., et al. 1965. Serum insulin-like activity in hypophysectomized and depancreatized (Houssay) dogs. Diabetes 14:658-662
56. Wolf, S., et al. 2010.Tratment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance.World J Gastroenterol 16:156-166
57. Wolkow, C.A., et al. 2000. Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science 290:147-150
58. Wright, P. H. 1960. Plasma-insulin activity in acromegaly and spontaneous hypoglycemia. Lancet 1:951-954
59. Yakar, S., et al. 1999.Normal growth and development in the absence of hepatic insulinlike growth factor I. Proc Natl Acad Sci USA 96:7324-7329
60. Zapf, J. 1993. IGFs: Function and clinical importance. 3.Role of insulin-like growth factor (IGF)II and IGF binding proteins in extrapancreatic tumour hypoglycemia. J Int Med 234:543-552
61. Zapf, J., E.R. Froesch, and R. E.Humbel. 1981.The insulin-like growth factors (IGF) of human serum: Chemical and biological characterization and aspects of their possible physiologic role. Curr Top Cell Regul 19:257-309.